Overlooked Therapy Revolutionizing Sickle Cell Care in Africa
Elijah TobsBy Elijah Tobs
Health
May 6, 2026 • 9:33 PM
5m5 min read
Verified
Source: Pexels
The Core Insight
Sickle cell disease affects 7.7 million worldwide, with over 75% of cases in Africa and 300,000 annual births in sub-Saharan Africa. Red blood cell exchange, an underutilized therapy, lowers sickle hemoglobin, prevents strokes, manages pain crises, and offers a repeatable alternative to bone marrow transplants without needing donors. Recent successful procedures highlight its potential to reduce hospitalizations and improve quality of life.
As the founder and primary investigative voice at Kodawire, Elijah Tobs brings over 15 years of experience in dissecting complex geopolitical and financial systems. His work is centered on the ethical governance of emerging technologies, the shifting architectures of global finance, and the future of pedagogy in a digital-first world. A staunch advocate for high-fidelity journalism, he established Kodawire to be a sanctuary for deep-dive intelligence. Moving away from the ephemeral nature of modern headlines, Kodawire delivers permanent, verified insights that challenge the status quo and empower the global reader.
Red Blood Cell Exchange: The Overlooked Lifeline for Sickle Cell Disease in Africa
Sickle-shaped red blood cells under microscope (Credit: Leo Freire via Pexels)
For people living with sickle cell disease, hope is often measured in small victories: a month without a pain crisis, fewer nights in emergency rooms, and the freedom to plan life without constant fear of the next episode. For parents and loved ones, hope means watching loved ones suffer less and live more fully.
Sickle cell disease is one of the most common inherited blood disorders worldwide, yet profoundly undertreated, especially in Africa, where the burden is highest. The World Health Organization estimates 7.7 million people worldwide live with sickle cell disease, with the vast majority in sub-Saharan Africa, a 40% increase since 2000. The condition causes over 300,000 deaths yearly.
Data indicate more than 75% of babies born with sickle cell disease worldwide are born on the African continent. Approximately 400,000 babies are born with sickle cell disease globally each year, with more than 300,000 in sub-Saharan Africa. Nigeria accounts for around 150,000 of these newborns annually, with prevalence projected to rise by 2050. Millions more in the African diaspora, including the United States, United Kingdom, Caribbean, and Europe, manage the lifelong impact.
Access to advanced treatments remains limited. Patients are often told meaningful care is only available abroad or that bone marrow transplant is the only solution, bringing frustration rather than relief.
Red Blood Cell Exchange: A Proven, Underutilized Therapy
Red blood cell exchange using advanced apheresis technology (Credit: Roger Brown via Pexels)
Red blood cell exchange is one of the most effective yet underutilized therapies for sickle cell disease. Clinical guidance from the American Society of Haematology recognizes it for stroke prevention, management of severe pain crises, and life-threatening complications like acute chest syndrome.
At the African Medical Centre of Excellence (AMCE), teams are delivering advanced therapies, including red blood cell exchange. The centre recently completed its first procedure using the Terumo Optia machine on a patient with sickle cell anaemia and chronic pain. It involved removing the patient’s sickled red cells and replacing them with haemoglobin AA red cells. The patient has remained pain-free since, illustrating the therapy's transformative potential.
Red blood cell exchange rapidly lowers sickle haemoglobin proportion, improves blood flow, and reduces progressive organ damage risk. It is used for refractory bone pain, preparation for stem cell transplantation, severe malaria parasitaemia, and carbon monoxide poisoning. By replacing unhealthy red cells with healthy ones, it directly addresses the disease's pathophysiology.
A More Accessible Alternative to Bone Marrow Transplant
Accessible therapy alternative to resource-intensive transplants (Credit: Marta Branco via Pexels)
Bone marrow transplantation is the only established curative treatment but is limited by suitable donor availability and is costly and resource-intensive, beyond reach for many. Effective long-term management is essential for improving quality of life and reducing complications.
Unlike bone marrow transplantation, red blood cell exchange is repeatable, requires no matched donor, and is increasingly accessible at AMCE for patients in Nigeria and across Africa. When performed regularly, it significantly reduces stroke risk in children and frequency of severe pain crises in adults.
For patients not eligible for transplant or seeking fewer hospitalizations and less pain, red blood cell exchange offers stability and dignity.
A Call to Patients, Families, and the Health Community
Families finding hope in local advanced care (Credit: Tima Miroshnichenko via Pexels)
Patients needing red blood cell exchange have an option at AMCE, not only for sickle cell disease but also for severe malaria parasitaemia or carbon monoxide poisoning. Families can access specialist care close to home with personalized plans.
Sickle cell disease inflicts a heavy toll across Africa and its diaspora, contributing to preventable suffering, hospitalizations, and early mortality. By introducing red blood cell exchange, AMCE is changing this reality, showing advanced interventions are achievable within Africa. This expands access, restores hope, improves quality of life, and empowers patients and families to manage blood disorders with dignity and confidence.
Red blood cell exchange removes sickled red cells and replaces them with healthy haemoglobin AA red cells, rapidly lowering sickle haemoglobin, improving blood flow, and reducing pain crises, stroke risk, and organ damage.
At the African Medical Centre of Excellence (AMCE) in Nigeria, where the first procedure using the Terumo Optia machine was recently completed on a sickle cell patient.
Unlike bone marrow transplantation, which requires a matched donor and is costly, red blood cell exchange is repeatable, needs no donor, and is more accessible for managing severe symptoms.
Patients like the one at AMCE have remained pain-free since the procedure, with reduced frequency of severe pain crises and stroke risk when performed regularly.
It is used for refractory bone pain, preparation for stem cell transplantation, severe malaria parasitaemia, and carbon monoxide poisoning.
Active Engagement
Was this information helpful?
Join Discussions
0 Thoughts
Editorial Team • Question of the Day
"Could red blood cell exchange change sickle cell care where you live?"
